Sankt Radegund bei Graz, Austria
Sankt Radegund bei Graz, Austria

Time filter

Source Type

Thonhofer M.,University of Graz | Weber P.,University of Graz | Gonzalez Santana A.,University of British Columbia | Tysoe C.,University of British Columbia | And 8 more authors.
Carbohydrate Research | Year: 2016

From an easily available partially protected analog of 1-deoxy-L-gulo-nojirimycin, by chain-branching at C-4 and suitable modification, lipophilic analogs of the powerful β-D-galactosidase inhibitor 4-epi-isofagomine have been prepared. New compounds exhibit considerably improved inhibitory activities when compared with the unsubstituted parent compound and may serve as leads toward new pharmacological chaperones for GM1-gangliosidosis and Morquio B disease. © 2016 Elsevier Ltd.


Thonhofer M.,University of Graz | Weber P.,University of Graz | Santana A.G.,University of British Columbia | Fischer R.,University of Graz | And 7 more authors.
Bioorganic and Medicinal Chemistry Letters | Year: 2016

From an easily available partially protected formal derivative of 1-deoxymannojirimycin, by hydroxymethyl chain-branching and further elaboration, lipophilic analogs of the powerful β-d-galactosidase inhibitor 4-epi-isofagomine have become available. New compounds exhibit improved inhibitory activities comparable to benchmark compound NOEV (N-octyl-epi-valienamine) and may serve as leads towards improved and more selective pharmacological chaperones for GM1-gangliosidosis. © 2016 Elsevier Ltd. All rights reserved.


PubMed | University of British Columbia, University of Graz and Laboratory of Metabolic Diseases
Type: | Journal: Carbohydrate research | Year: 2016

From an easily available partially protected analog of 1-deoxy-L-gulo-nojirimycin, by chain-branching at C-4 and suitable modification, lipophilic analogs of the powerful -D-galactosidase inhibitor 4-epi-isofagomine have been prepared. New compounds exhibit considerably improved inhibitory activities when compared with the unsubstituted parent compound and may serve as leads toward new pharmacological chaperones for GM1-gangliosidosis and Morquio B disease.


PubMed | University of British Columbia, University of Graz and Laboratory of Metabolic Diseases
Type: Journal Article | Journal: Bioorganic & medicinal chemistry letters | Year: 2016

From an easily available partially protected formal derivative of 1-deoxymannojirimycin, by hydroxymethyl chain-branching and further elaboration, lipophilic analogs of the powerful -d-galactosidase inhibitor 4-epi-isofagomine have become available. New compounds exhibit improved inhibitory activities comparable to benchmark compound NOEV (N-octyl-epi-valienamine) and may serve as leads towards improved and more selective pharmacological chaperones for GM1-gangliosidosis.

Loading Laboratory of Metabolic Diseases collaborators
Loading Laboratory of Metabolic Diseases collaborators